Cargando…
A functional signal profiling test for identifying a subset of HER2-negative breast cancers with abnormally amplified HER2 signaling activity
The results of clinical trials evaluating the efficacy of HER2 inhibitors in patients with breast cancer indicate that the correlation between HER2 receptor levels and patient outcomes is as low as 50%. The relatively weak correlation between HER2 status and response to HER2-targeting drugs suggests...
Autores principales: | Huang, Yao, Burns, David J, Rich, Benjamin E, MacNeil, Ian A, Dandapat, Abhijit, Soltani, Sajjad M., Myhre, Samantha, Sullivan, Brian F, Furcht, Leo T, Lange, Carol A, Hurvitz, Sara A, Laing, Lance G |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5346661/ https://www.ncbi.nlm.nih.gov/pubmed/27713176 http://dx.doi.org/10.18632/oncotarget.12480 |
Ejemplares similares
-
Development of a test that measures real-time HER2 signaling function in live breast cancer cell lines and primary cells
por: Huang, Yao, et al.
Publicado: (2017) -
Functional signaling test identifies HER2 negative breast cancer patients who may benefit from c-Met and pan-HER combination therapy
por: MacNeil, Ian A., et al.
Publicado: (2022) -
New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified
por: MacNeil, Ian A., et al.
Publicado: (2020) -
Targetable HER3 functions driving tumorigenic signaling in HER2-amplified cancers
por: Campbell, Marcia R., et al.
Publicado: (2022) -
HER-3 expression in HER-2-amplified breast carcinoma
por: Czopek, Jacek, et al.
Publicado: (2013)